Navigation Links
Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors
Date:4/21/2010

o the risk and uncertainties inherent in the Orexigen business, including, without limitation: additional analyses of data from the Contrave Phase 3 trials and any other clinical trials of Contrave may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted clinical trials; the FDA may not agree with the Company's interpretation of efficacy and safety results; the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDA for Contrave; the third parties on whom Orexigen relies to assist with the development programs for Contrave, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. All conclusions and determinations contained herein are subject to the Company's further analysis of the clinical data. The ultimate determination of the safety and efficacy of Contrave will be made by the FDA and other relevant regulatory authorities.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014   OTEMR, Inc. , ONETOUCH ... EHR certification, which designates that the software is capable ... and Stage 2 Meaningful Use measures required to qualify ... (ARRA).  ONETOUCH EMR 2.0 was certified on July 14, ... the National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant ...
(Date:9/17/2014)... , Sept. 17, 2014  Millions of people suffer from ... disease. Recently the FDA approved the launch ... an innovative implant device developed by Spinal Kinetics, which may ... neck and or arm pain. Hospital for Special Surgery (HSS), ... only hospital in New York City ...
(Date:9/17/2014)... Calif. , Sept. 17, 2014   ... data analytics solution that brings complete visibility to ... risks in an ever-evolving reimbursement landscape. Powered by ... brings transparency to the critical point between patient ... impact revenue. The solution will improve revenue capture, ...
Breaking Medicine Technology:OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... SPRING, Md., Nov. 23, 2011 The FDA today ... owner for substituting ingredients and products without noting the ... filed on behalf of the FDA by the U.S. ... and distributing more than 400 products for being in ...
... 23, 2011 /PRNewswire-iReach/ -- Now in its 13th ... discuss, investigate, and learn about the latest in pharmaceutical technology. ... at the Crocus Expo, International Exhibition Centre, in Moscow. ... sustainable air filters — a key ...
Cached Medicine Technology:FDA Takes Enforcement Action Against Pennsylvania Dietary Supplement Maker 2FDA Takes Enforcement Action Against Pennsylvania Dietary Supplement Maker 3Camfil Farr to Discuss Sustainable Air Filtration at PHARMTECH 2011 2Camfil Farr to Discuss Sustainable Air Filtration at PHARMTECH 2011 3
(Date:9/17/2014)... N.J. (PRWEB) September 17, 2014 ... advanced delivery technologies and development solutions for drugs, ... launch of OptiPact™, an integrated service and technology ... compaction, and provided from the company’s 450,000 sq. ... describes Catalent’s ability to integrate optimal formulation, development, ...
(Date:9/17/2014)... Positive messages about the health benefits of quitting smoking ... study suggests. Although smokers who think quitting will ... harmful effects of smoking, researchers found smokers who believe ... "gain-framed," or positive, messages about how quitting will improve ... mix of both types of messages might get more ...
(Date:9/17/2014)... New York (PRWEB) September 17, 2014 ... involving the Conserve line of metal-on-metal hip replacements ... underway in U.S. District Court, Northern District of ... updated Case List issued by the U.S. Judicial ... at least 397 product liability claims have been ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Smart Flour ... Picks by Progressive Grocer, a leading trade magazine targeted ... awarded for originality and flavor, among other attributes. Smart ... an Editor’s Pick in the September print issue of ... website. , The pizza won based on its superior ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 Leading ... to announce the launch of its new vegan and ... is extremely effective and provided the results skincare testers ... to create a gentle yet active mask that provided ... Lake Louise.” , This Sugar Cane Fruit Mask combines ...
Breaking Medicine News(10 mins):Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2
... Month, BETHESDA, Md., Jan. 3 AABB (formerly ... individuals,participating in the presidential elections to continue making an ... the month of,January, National Blood Donor Month (NBDM) provides ... give blood at a time of the year when,it ...
... ... Refractory Patients to Replace Current TIME-2 ... Trial ... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today announced that the Tanespimycin in,Myeloma Evaluation or TIME-1 pivotal Phase ...
... young people,s blood sugar levels, study finds , THURSDAY, Jan. ... three nights running has the same negative effect on the ... pounds, diabetes researchers report. , In fact, young adults ... their risk of type 2 diabetes, according to a study ...
... others with a family history of ... glaucoma are particularly vulnerable, SAN FRANCISCO, Jan. 3 ... do not notice as their peripheral,vision diminishes or blind spots occur. ... disease are unaware of their condition.,January is Glaucoma Awareness Month, and ...
... Abbott (NYSE: ABT ),will announce its financial results ... on Wednesday, Jan. 23, 2008, before the market opens., ... webcast of the earnings,conference call at 8 a.m. Central ... Investor Relations Web site at, http://www.abbottinvestor.com . An archived ...
... the story is the same: New,Year,s resolutions made, New ... be combined with online health tools and expert advice,to ... growing health,properties on the Internet -- launched "Resolutions 2.0," ... video from Revolution Health at:, http://media.medialink.com/WebNR.aspx?story=34279 ) "Resolutions ...
Cached Medicine News:Health News:Exercise Your Right to Vote and Continue to Make a Difference by Giving Blood in 2008 2Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 2Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 3Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 4Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 5Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 6Health News:Lack of Deep Sleep Raises Diabetes Risk 2Health News:Lack of Deep Sleep Raises Diabetes Risk 3Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 2Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 3Health News:VIDEO from Medialink and Revolution Health: RevolutionHealth.com Launches 'Resolutions 2.0' 2
... 200 series offers a range of ... The design delivers therapy to meet ... promote results in commercial and clinical ... differentiator in the SleepStyle 200 series ...
... The SleepStyle 200 series offers a ... CPAP models. The design delivers therapy ... Performance features promote results in commercial ... The strongest differentiator in the SleepStyle ...
The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
The S7 Lightweight offers the comfort and reliability of the award-winning S7 series in a convenient, affordable device....
Medicine Products: